Abstract
Inoviv is pleased to unite leading drug developers and industry experts to discuss NeuroKey-3™, a recent advancement in disease-targeted LC-MS biomarker assays for Alzheimer’s (AD) and Dementia. The discussion will be led by Inoviv’s Commercial SVP, Ben Gonzales, and Chief Scientific Officer, Ernestas Sirka.
Current treatments for neurodegenerative diseases are restricted. The advancement of effective medicines, including efficacy assessment beyond traditional cognitive tests, heavily relies on an optimal biomarker strategy for disease identification, monitoring, and stratification. Needless to say, the current assay development and validation process is costly and laborious, most of which also do not meet the regulatory submission criteria.
To address these challenges, Inoviv developed NeuroKey-3™, a proprietary fully quantitative multiplexed IP-MS assay that exploits analytical algorithms, workflows, and internal standards, to provide unparalleled reproducibility, robustness, sensitivity with a linear dynamic range over six orders of magnitude.
During this webinar, our proteomics experts will:
- Demonstrate how NeuroKey-3™ quantifies key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer’s Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and more.
- Discuss fully quantitative, multiplexed LC-MS biomarker analysis to support drug discovery and development.
- Present case studies, describing how neurological therapeutic developers have harnessed NeuroKey-3™ to generate valuable molecular insights for their clinical programs.
Speaker: Ben Gonzales
Senior Vice President, Commercial
Ben Gonzales, SVP Commercial at Inoviv, spearheads business development, marketing, and product strategy for the company’s fully validated, multiplexed, mass spectrometry-based proteomics assays. With over 20 years of leadership in biotech and pharma, Ben specializes in proteomics, having successfully developed and commercialized innovative technologies in diagnostics and R&D. Previously, he served as General Manager at Biognosys Inc., expanding US operations in support of mass spectrometry-based proteomics. Ben’s career also includes pivotal roles such as Product Manager at SomaLogic, where he contributed to the commercialization of cutting-edge technologies. His expertise drives Inoviv’s growth and leadership in proteomics solutions.
Speaker: Ernestas Sirka
Chief Scientific Officer
Ernestas Sirka is a seasoned biochemistry expert with extensive experience in clinical test development, distinguished by roles at Pfizer and UCL. Notably, he has pioneered the development of four clinical tests that continue to underpin modern clinical practice, cementing his reputation as a trailblazer in medical diagnostics. Ernestas’ pursuit of utilizing novel scientific applications to advance healthcare has driven multiple academic accolades, including peer reviewed publications in Nature Medicine, Journal of Neuroscience, and more. Now acting as Chief Scientific Officer at Inoviv, Ernestas leads groundbreaking initiatives that push the boundaries of medical science, driving innovation to shape the future of healthcare.
